Parallel Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Parallel Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$238K	Hold	17,887	–	–	﹤0.01%	1168
2026 Q1	$167K	Hold	17,887	–	–	﹤0.01%	1276
2025 Q4	$134K	Sell	17,887 -1,858	-9%	-$18.8K	﹤0.01%	1301
2025 Q3	$172K	Hold	19,745	–	–	﹤0.01%	1126
2025 Q2	$73.3K	Hold	19,745	–	–	﹤0.01%	1520
2025 Q1	$63.8K	Hold	19,745	–	–	﹤0.01%	1500
2024 Q4	$110K	Sell	19,745 -33	-0.2%	-$259	﹤0.01%	1218
2024 Q3	$214K	Hold	19,778	–	–	0.01%	894
2024 Q2	$415K	Buy	19,778 +19,745	+59,833%	+$495K	0.01%	591
2024 Q1	$1.05K	Hold	33	–	–	﹤0.01%	2925
2023 Q4	$669	Buy	+33	New	+$434	﹤0.01%	3014

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Parallel Advisors's FDMT Position: Q2 2026 in Review

Parallel Advisors held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 17,887 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #1168.

Parallel Advisors first reported a position in FDMT in Q4 2023 and has held it in 11 quarters since. The position peaked at $415K in Q2 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Parallel Advisors held 17,887 shares of 4D Molecular Therapeutics worth $238K as of Q2 2026.
Parallel Advisors left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
4D Molecular Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1168 holding.
Parallel Advisors first reported a position in 4D Molecular Therapeutics in Q4 2023 and has held it in 11 quarters since.
Parallel Advisors's 4D Molecular Therapeutics position peaked at $415K in Q2 2024.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.